Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
141-160 of 1,307 trials

Preeclampsia Intervention 4: Metformin for Preterm Preeclampsia

We are studying whether daily metformin can help prolong pregnancy in women with preterm preeclampsia. We also want to see if it improves outcomes for newborns, like increasing birth weight and reducing time in neonatal care.

Preeclampsia>2 yearsConfirmation phase (III)Standard MedicinesGynecology and ObstetricsInternal Medicine

Advanced Melanoma: Tebentafusp Treatment Study

We are studying a new treatment for advanced melanoma in patients who have already been treated. This trial compares tebentafusp alone and with pembrolizumab against standard treatment options to see if it improves survival and quality of life.

Uveal MelanomaMetastatic Malignant MelanomaPreviously Treated Non-Ocular Advanced MelanomaEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Dermatomyositis and Polymyositis: PF-06823859 Study

We are testing a new medication to see if it helps reduce muscle and skin symptoms in adults with active dermatomyositis or polymyositis. This study compares the new treatment to a placebo to evaluate its effectiveness.

Polymyositis and DermatomyositisConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Endometrial Cancer: Durvalumab with Chemotherapy

We are studying a new treatment combining durvalumab with standard chemotherapy for patients with advanced or recurrent endometrial cancer. The goal is to see if this approach improves survival and quality of life compared to chemotherapy alone.

Endometrial Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Stage III Lung Cancer: MK-7684A Treatment Study

We are studying a new treatment combining MK-7684A with radiation and chemotherapy for patients with unresectable Stage III lung cancer. This trial compares it to standard treatment followed by Durvalumab.

Non-small cell lung cancer≤3 monthsConfirmation phase (III)Monitoring phase (IV)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Gastroesophageal Reflux Disease in Infants: Diet vs. Medication

We are studying whether a cow's milk-free diet or a medication helps reduce reflux episodes in infants with GERD. Parents will track their baby's symptoms using an app during the trial.

Gastroesophageal Reflux Disease (GERD)Cows' Milk AllergyConfirmation phase (III)Monitoring phase (IV)Investigational MedicinesGastroenterologyPediatrics

Follicular Lymphoma: Radiotherapy with Obinutuzumab

We are studying whether adding Obinutuzumab to local radiotherapy improves outcomes for patients with early-stage Follicular Lymphoma. This trial will help us understand the effectiveness and safety of this combination treatment.

Early Stage Follicular Lymphoma3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Iron Supplement for Better Recovery After Major Surgery

We are studying whether Ferric Carboxymaltose can improve recovery and reduce complications for patients who have undergone major surgeries with significant blood loss. This trial will help us understand its impact on anemia and overall quality of life.

Anemia>2 yearsConfirmation phase (III)Investigational MedicinesCardiologyGastroenterologyHematology

Aggressive B-cell Non-Hodgkin Lymphoma: Odronextamab Study

We are studying how well odronextamab works compared to standard treatments for adults with previously treated aggressive B-cell non-Hodgkin lymphoma. The trial will also look at safety and how treatment affects daily life.

B-Cell Non-Hodgkin's Lymphoma1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Diffuse Large B-Cell Lymphoma: Odronextamab vs. Rituximab

We are studying how well odronextamab combined with chemotherapy works compared to rituximab with chemotherapy in patients who have not yet received treatment for diffuse large B-cell lymphoma. The trial aims to evaluate safety and effectiveness in this patient group.

Diffuse Large B-cell Lymphoma3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Actinic Keratosis: Sinecatechins Ointment Study

We are studying a green tea extract ointment for adults with actinic keratosis on the scalp and face. The goal is to see if it clears skin lesions better than a placebo and to assess its safety.

Actinic Keratosis3-6 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesDermatology

Idiopathic Inflammatory Myopathy: Efgartigimod Treatment

We are studying the long-term safety and effects of a new injection for adults with active idiopathic inflammatory myopathy. This research aims to see if it can help reduce steroid use and improve health outcomes.

Active Idiopathic Inflammatory Myopathy>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Chemotherapy-Induced Polyneuropathy: Aconite Pain Oil Study

We are studying whether Aconite Pain Oil can help prevent and reduce symptoms of chemotherapy-induced polyneuropathy in cancer patients. The goal is to improve quality of life and manage symptoms during treatment.

Chemotherapy-Induced Polyneuropathy>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesNeurologyOncology

Kidney Stones: Furosemide Injection Study

We are investigating whether a Furosemide injection after kidney stone removal improves the chances of being stone-free and reduces the risk of infections. This study involves patients undergoing flexible ureteroscopy for kidney stones.

Kidney Stones>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementUrology

ADHD Treatment: Dexamfetamine Formulations

We are studying two types of dexamfetamine sulfate in adults with ADHD to see if they are more effective than a placebo. The trial will also evaluate the safety of these medications.

Attention Deficit Hyperactivity Disorder (ADHD)6-12 monthsConfirmation phase (III)11-15 visitsStandard MedicinesNeurologyPsychiatry

Eptinezumab for Migraines in Children and Adolescents

We are studying the long-term safety of eptinezumab in children and teens aged 6 to 17 who experience chronic or episodic migraines. This research aims to ensure the medication is safe for young patients.

Migraine6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

HIV Prevention: TAF/FTC Medication

We are testing a new event-driven medication for HIV prevention in men who have sex with men in Thailand and France. The study aims to assess its effectiveness, safety, and how well participants accept it.

HIV Prevention>2 yearsConfirmation phase (III)Infectious Diseases

Prostate Cancer: AAA617 Treatment Study

We are studying a new drug, AAA617, for adult men with oligometastatic prostate cancer to see if it can delay disease progression compared to standard observation. This trial aims to evaluate its effects on survival and quality of life.

Oligometastatic Prostate Cancer3-6 monthsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Lung Cancer Treatment: DZD9008 vs. Chemotherapy

We are studying a new medication, DZD9008, for patients with advanced non-small cell lung cancer that has a specific genetic mutation. The goal is to see if it works better than standard chemotherapy.

Advanced Non-Small Cell Lung Cancer with EGFR MutationConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPulmonology

Severe Infections: MODIFY Trial

We are testing a new method to guide antibiotic treatment for severe infections, aiming to reduce unnecessary antibiotic use. This study will also evaluate how this approach impacts recovery and health outcomes.

Sepsis>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine